Avalo Therapeutics Inc.

Avalo Therapeutics Inc.

World Rank (Aug-2026)
9013
Market Cap (Aug-2026)
1.051 Billion USD
Market Cap (Mar-08-2026)
0.320 Billion USD
World Rank (Jan-05-2024)
31,979
Market Cap (Jan-05-2024)
0.007 Billion USD
World Rank (Jul-30-2023)
33,602
Market Cap (Jul-30-2023)
0.003 Billion USD
World Rank (Jan-07-2022)
21,658
Market Cap (Jan-07-2022)
0.117 Billion USD
Headquarters Country
USA
Nasdaq / NYSE Code
AVTX
Headquarters City/State
Maryland
World Region
Americas
World Subregion
Northern America
Annual Revenue in USD
0 Million USD
Annual Operating Income in USD
-73 Million USD
Annual Net Income in USD
-78 Million USD
Annual Results for Period Ending
For year ending December-2025
Total Assets in USD
116 Million USD
Total Liabilities in USD
33 Million USD
Total Equity in USD
83 Million USD
Balance Sheet for Period Ending
As of December-2025
Business Sector
Healthcare
Biotechnology
Biopharmaceutical
Company Website
AVALO THERAPEUTICS, INC.
Company Profile
Avalo Therapeutics, Inc. is a biopharmaceutical company that discover, develop and commercialize highly targeted therapeutics in areas of significant unmet clinical need. The headquarters is in USA.
Facts About Company
Avalo Therapeutics, Inc. company annual revenue is 18 million USD and annual net loss -41 million USD as on Dec-2022.
IPO Year
2015
Nasdaq Sector
Health Care
Nasdaq Industry
Biotechnology: Pharmaceutical Preparations

Share